PD-1/PD-L1抑制剂引起免疫相关性肺炎的研究进展

doi:10.3760/cma.j.cn371439-20200609-00091

国际肿瘤学杂志 ›› 2020, Vol. 47 ›› Issue (10): 627-629.doi: 10.3760/cma.j.cn371439-20200609-00091

PD-1/PD-L1抑制剂引起免疫相关性肺炎的研究进展

宋博, 邬明歆, 贾英杰, 李小江()

天津中医药大学第一附属医院肿瘤科 300381

收稿日期:2020-06-09 修回日期:2020-07-01 出版日期:2020-10-08 发布日期:2020-11-20
通讯作者: 李小江 E-mail:zxqlovelxj@126.com
基金资助:
国家中医药管理局中医药循证能力建设项目(2019XZZX-ZL007)

Research progress of immune-related pneumonia caused by PD-1/PD-L1 inhibitor

Song Bo, Wu Mingxin, Jia Yingjie, Li Xiaojiang()

Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China

Received:2020-06-09 Revised:2020-07-01 Online:2020-10-08 Published:2020-11-20
Contact: Li Xiaojiang E-mail:zxqlovelxj@126.com
Supported by:
Evidence-based Capacity Building Project of Chinese Medicine by the State Admini-stration of Traditional Chinese Medicine(2019XZZX-ZL007)

摘要/Abstract

摘要：

程序性死亡蛋白-1/程序性死亡蛋白配体-1抑制剂引起的免疫相关性肺炎发生率低,但风险较高。有肺部基础疾病与既往接受过胸部放疗的非小细胞肺癌患者更易发生肺炎,但其临床症状不典型,导致患者生存获益下降。及早延缓免疫疗法并合理使用糖皮质激素与免疫抑制剂可缓解临床症状,改善预后。

关键词: PD-1, PD-L1, 免疫相关性肺炎

Abstract:

The incidence of immune-related pneumonia caused by programmed death-1/programmed death ligand-1 inhibitors is low, but the risk is high. Patients with non-small cell lung cancer who have pre-existing lung diseases or have received chest radiotherapy are more likely to develop pneumonia, but their clinical symptoms are not typical, which reduces the survival benefit of patients. Delaying immunotherapy early and rationally using glucocorticoids and immunosuppressants can relieve clinical symptoms and improve prognosis.

Key words: PD-1, PD-L1, Immune-associated pneumonia

宋博, 邬明歆, 贾英杰, 李小江. PD-1/PD-L1抑制剂引起免疫相关性肺炎的研究进展[J]. 国际肿瘤学杂志, 2020, 47(10): 627-629.

Song Bo, Wu Mingxin, Jia Yingjie, Li Xiaojiang. Research progress of immune-related pneumonia caused by PD-1/PD-L1 inhibitor[J]. Journal of International Oncology, 2020, 47(10): 627-629.

参考文献 24

[1]	Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper[J]. Ann Oncol, 2016,27(4):559-574. DOI: 10.1093/annonc/mdv623.
[2]	Postow MA. Managing immune checkpoint-blocking antibody side effects[J]. Am Soc Clin Oncol Educ Book, 2015: 76-83. DOI: 10.14694/EdBook_AM.2015.35.76. pmid: 25993145
[3]	张宁刚, 尚昆, 曹邦伟. 免疫检查点抑制剂治疗恶性肿瘤的不良反应及处理[J]. 中国医院用药评价与分析, 2018,18(4):435-437. DOI: 10.14009/j.issn.1672-2124.2018.04.002.
[4]	Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis[J]. JAMA Oncol, 2016,2(12):1607-1616. DOI: 10.1001/jamaoncol.2016.2453.
[5]	刘甜, 胡毅. PD-1/PD-L1抑制剂免疫相关性不良反应及其处理综述[J]. 解放军医学院学报, 2018,39(3):251-254. DOI: 10.3969/j.issn.2095-5227.2018.03.018.
[6]	Wu J, Hong D, Zhang X, et al. PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis[J]. Sci Rep, 2017,7:44173. DOI: 10.1038/srep44173.
[7]	Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper[J]. Ann Oncol, 2016,27(4):559-574. DOI: 10.1093/annonc/mdv623. doi: 10.1093/annonc/mdv623 pmid: 26715621
[8]	Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2017,35(7):709-717. DOI: 10.1200/JCO.2016.68.2005. doi: 10.1200/JCO.2016.68.2005 pmid: 27646942
[9]	Nishino M, Ramaiya NH, Hatabu H, et al. PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy[J]. Br J Haematol, 2018,180(5):752-755. DOI: 10.1111/bjh.14441.
[10]	Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4): iv264-iv266. DOI: 10.1093/annonc/mdy162. pmid: 29917046
[11]	Nishino M, Sholl LM, Hodi FS, et al. Anti-PD-1-related pneumonitis during cancer immunotherapy[J]. N Engl J Med, 2015,373(3):288-290. DOI: 10.1056/NEJMc1505197.
[12]	冀寿健, 徐建明. 免疫检查点抑制剂相关不良反应的研究进展[J]. 中国肿瘤临床与康复, 2018,25(7):894-896. DOI: 10.13455/j.cnki.cjcor.2018.07.036.
[13]	Yamaguchi T, Shimizu J, Hasegawa T, et al. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: a retrospective analysis[J]. Lung Cancer, 2018,125:212-217. DOI: 10.1016/j.lungcan.2018.10.001. doi: 10.1016/j.lungcan.2018.10.001 pmid: 30429022
[14]	Hwang WL, Niemierko A, Hwang KL, et al. Clinical outcomes in patients with metastatic lung cancer treated with PD-1/PD-L1 inhibitors and thoracic radiotherapy[J]. JAMA Oncol, 2018,4(2):253-255. DOI: 10.1001/jamaoncol.2017.3808.
[15]	Su Q, Zhu EC, Wu JB, et al. Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis[J]. Front Immunol, 2019,10:108. DOI: 10.3389/fimmu.2019.00108. doi: 10.3389/fimmu.2019.00108 pmid: 30778352
[16]	李婧. 以PD-1为代表的免疫检查点分子单抗在肿瘤治疗中的应用研究进展[J]. 细胞与分子免疫学杂志, 2018,34(7):650-654. DOI: 10.13423/j.cnki.cjcmi.008660.
[17]	Davies M, Duffield EA. Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events[J]. Immunotargets Ther, 2017,6:51-71. DOI: 10.2147/ITT.S141577. doi: 10.2147/ITT.S141577 pmid: 28894725
[18]	Sui JD, Wang Y, Wan Y, et al. Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies[J]. Drug Des Devel Ther, 2018,12:1645-1657. DOI: 10.2147/DDDT.S167077.
[19]	闫晨霞, 张然, 王乃栩. 抗PD-1/PD-L1单抗的免疫相关不良反应[J]. 华西药学杂志, 2018,33(3):333-336. DOI: 10.13375/j.cnki.wcjps.2018.03.028.
[20]	彭智, 袁家佳, 王正航, 等. ASCO/NCCN免疫治疗毒性管理指南解读[J]. 肿瘤综合治疗电子杂志, 2018,4(2):38-47.
[21]	Balaji A, Verde F, Suresh K, et al. Pneumonitis from anti-PD-1/PD-L1 therapy[J]. Oncology (Williston Park), 2017,31(10):739-754.
[22]	O'Kane GM, Labbé C, Doherty MK, et al. Monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer[J]. Oncologist, 2017,22(1):70-80. DOI: 10.1634/theoncologist.2016-0164.
[23]	中华医学会呼吸病学分会肺癌学组. 免疫检查点抑制剂相关肺炎诊治专家共识[J]. 中华结核和呼吸杂志, 2019,42(11):820-825. DOI: 10.3760/cma.j.issn.1001-0939.2019.11.007.
[24]	Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2017,35(7):709-717. DOI: 10.1200/JCO.2016.68.2005. doi: 10.1200/JCO.2016.68.2005 pmid: 27646942

PD-1/PD-L1抑制剂引起免疫相关性肺炎的研究进展

Research progress of immune-related pneumonia caused by PD-1/PD-L1 inhibitor

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 24

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王悦, 呼群, 侯英伟. 表观遗传修饰对肿瘤PD-L1表达调控的研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 345-348.
[2]	宁婷婷, 胡钦勇. 二甲双胍在肿瘤免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(5): 292-295.
[3]	丁心静, 丁江华. 皮肤免疫相关不良事件与PD-1/PD-L1抑制剂临床疗效相关性的研究进展[J]. 国际肿瘤学杂志, 2022, 49(4): 225-228.
[4]	谢红霞, 左金辉, 廖冬颖, 邓仁芬, 姚杨, 贾英杰, 李小江, 孔凡铭. PD-L1抑制剂在非小细胞肺癌中的应用[J]. 国际肿瘤学杂志, 2022, 49(2): 111-115.
[5]	李宁, 张玢琪. 免疫检查点抑制剂在子宫内膜癌中的应用[J]. 国际肿瘤学杂志, 2022, 49(2): 125-128.
[6]	欧惠仪, 王越, 彭承宏. PD-L1与Treg在肿瘤免疫及治疗中的相关性[J]. 国际肿瘤学杂志, 2021, 48(6): 350-353.
[7]	丁艳, 汪红艳. PD-1/PD-L1抑制剂在食管鳞状细胞癌治疗中的进展[J]. 国际肿瘤学杂志, 2021, 48(2): 113-116.
[8]	赵丽丽, 赵文文, 冯青青, 赵文飞, 张雪, 井文君, 魏红梅. 沉默PD-L1表达对胃癌细胞生物学行为的影响[J]. 国际肿瘤学杂志, 2021, 48(12): 705-710.
[9]	曹纯, 何文琪, 晏军. 免疫检查点抑制剂在小细胞肺癌治疗中的应用[J]. 国际肿瘤学杂志, 2021, 48(12): 747-750.
[10]	薛晨, 赵月, 石光, 唐艳. PD-1/PD-L1抑制剂在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2020, 47(5): 312-315.
[11]	徐阳涛, 陈彪, 何晓琴, 徐细明. 免疫治疗超进展的研究进展[J]. 国际肿瘤学杂志, 2020, 47(12): 737-740.
[12]	张李卓, 钱杨洋, 郑国湾, 葛明华. PD-1/PD-L1在肿瘤中的机制研究及其在甲状腺癌中的诊治价值[J]. 国际肿瘤学杂志, 2020, 47(1): 39-42.
[13]	白馨雅, 张金梦, 孙洋, 安永恒. 免疫检查点抑制剂在晚期非小细胞肺癌综合治疗中的应用[J]. 国际肿瘤学杂志, 2019, 46(8): 500-504.
[14]	何方, 高艳, 齐海燕, 李嵚, 许崇安. 化疗联合PD-1抑制剂一线治疗Lewis肺癌移植瘤的疗效及其调控机体细胞免疫功能的机制[J]. 国际肿瘤学杂志, 2019, 46(8): 453-459.
[15]	胡梦雪，许斌，于金明，宋启斌. PD-L1/TGF-β双功能抑制剂融合蛋白M7824研究进展[J]. 国际肿瘤学杂志, 2019, 46(5): 281-284.